Zhejiang Huahai Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Zhejiang Huahai Pharmaceutical has a total shareholder equity of CN¥9.0B and total debt of CN¥6.9B, which brings its debt-to-equity ratio to 77.1%. Its total assets and total liabilities are CN¥19.6B and CN¥10.6B respectively. Zhejiang Huahai Pharmaceutical's EBIT is CN¥1.8B making its interest coverage ratio 10.7. It has cash and short-term investments of CN¥1.5B.
Anahtar bilgiler
77.1%
Borç/özkaynak oranı
CN¥6.91b
Borç
| Faiz karşılama oranı | 10.7x |
| Nakit | CN¥1.52b |
| Eşitlik | CN¥8.95b |
| Toplam yükümlülükler | CN¥10.60b |
| Toplam varlıklar | CN¥19.56b |
Son finansal sağlık güncellemeleri
Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25
Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28Recent updates
Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
Oct 22Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 20Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings
May 06Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel
Mar 22Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600521's short term assets (CN¥8.0B) exceed its short term liabilities (CN¥5.7B).
Uzun Vadeli Yükümlülükler: 600521's short term assets (CN¥8.0B) exceed its long term liabilities (CN¥4.9B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600521's net debt to equity ratio (60.2%) is considered high.
Borcun Azaltılması: 600521's debt to equity ratio has increased from 76.8% to 77.1% over the past 5 years.
Borç Kapsamı: 600521's debt is well covered by operating cash flow (38.3%).
Faiz Kapsamı: 600521's interest payments on its debt are well covered by EBIT (10.7x coverage).